Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06383988
Other study ID # IRB000112187
Secondary ID NCI-2023-10870Le
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2024
Est. completion date January 2026

Study information

Verified date April 2024
Source Wake Forest University Health Sciences
Contact Karen Craver
Phone 336-716-0891
Email NCORP@wakehealth.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical trial that tests the feasibility of a web based caregiver support resource, along with caregiver navigation sessions for caregivers of patients with stage II-IV lung cancer. The Caregiver Oncology Needs Evaluation Tool (CONNECT) is a novel web-based intervention designed for the community oncology setting, to systematically connect lung cancer caregivers with tailored supportive care resources. Lung cancer caregivers provide critical and challenging care for their loved ones and are at risk for their own negative psychosocial and physical outcomes. Implementing the CONNECT program along with caregiver navigation may provide additional support to caregivers of patients with stage II-IV lung cancer.


Description:

This study is a multi-site randomized pilot trial enrolling 120 lung cancer caregiver-patient dyads (i.e., lung cancer caregivers (n=120) and their care-recipients (n=120)) across approximately 8-12 practices to assess the multi-site feasibility of a caregiver technology-based intervention (CONNECT) to identify caregivers' needs and connect them with supportive care resources. Caregivers will be randomized 1:1:1 to either the CONNECT intervention, usual care comparison group or generic resource list comparison group. CONNECT is a web-based intervention that empowers and educates caregivers about the benefits of supportive care services and systematically identifies unmet needs to connect lung cancer caregivers with tailored supportive care resources. The Central Caregiver Navigator will assist caregivers with resolving barriers to accessing resources and work with the Local Practice Referral Coordinator to process referrals. Caregivers and patients will complete measures at baseline (prior to caregiver randomization), and 12 and 24 weeks after baseline. Feasibility measures (retention, accrual rates, and participation) will be evaluated to inform the future trial. The Local Practice Referral Coordinator for each practice will report on time needed for practice participation, referral processes, and communication processes with the Central Caregiver Navigator. Participants (i.e., patients or care-recipients) will be asked to complete study surveys at three time points: - After consenting and before randomization of participant and caregiver. (Initial survey) - Approximately 12 weeks after completing the first survey (12-week survey) - Approximately 24 weeks after completing the first survey (24-week survey) Each survey will take about 30-45 minutes to complete. The forms will ask about things such as demographics (gender, race, etc.), cancer symptoms, satisfaction with cancer care and health behaviors. You don't have to answer any question that makes you feel uncomfortable. These surveys can be done remotely over the internet, in the clinic, by phone or by mail. Caregivers will also complete surveys at three time points and will be assigned to 1 of 3 study groups: - Group 1 will be given the usual care provided at your clinic. At the completion of the study, this group will be given the generic supportive care resource list for their use that Group 2 received. - Group 2 will be provided with a generic supportive care resource list. - Group 3 will be asked to watch a brief video and complete the web-based CONNECT program either in the clinic or on your own device. The CONNECT program is designed to help identify any unmet needs and connect the caregiver with tailored supportive care resources, based on specific needs. The CONNECT Navigator will follow-up with within 2 business days of completion of the program and again 4 weeks later. Caregiver Participants (Group 1, 2 and 3) will be asked to complete study surveys at three time points: - After consenting and before randomization of participant and caregiver. (Initial survey) - Approximately 12 weeks after completing the first survey (12-week survey) - Approximately 24 weeks after completing the first survey (24-week survey) Each survey will take about 35-45 minutes to complete. The forms will ask about things such as demographics (gender, race, etc.), caregiving experience, use of supportive care resources, quality of life, mood, and social needs (housing, transportation, utilities, etc). You don't have to answer any question that makes you feel uncomfortable.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 240
Est. completion date January 2026
Est. primary completion date October 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Patient Inclusion Criteria: - Must be = 18 years of age, as this study is focused on the experience of adult patient-caregiver dyads - Must have a current diagnosis of new or recurrent stage II-IV lung cancer - Must be enrolled after the start of anticancer systemic therapy (+/- radiation therapy) with at least 9 weeks of any planned anticancer treatment remaining - Eastern Cooperative Oncology Group (ECOG) performance status rating of level 0, 1, or 2 - Must be receiving unpaid care from a caregiver who meets the study caregiver criteria and who is willing to participate Caregiver Inclusion Criteria: - Must be =18 years of age, as this study is focused on the experience of adult patient-caregiver dyads - Must be providing the majority of the unpaid care during cancer treatment for a patient who meets the patient criteria and who is willing to participate - Must have access to the internet at home or be willing to use CONNECT in the clinic - Must have a telephone to complete sessions with the central caregiver navigator Patient Exclusion Criteria: - Post-treatment survivors at the time of study enrollment - Enrolled in hospice care - Unable to read and communicate in English Caregiver Exclusion Criteria: - Currently receiving cancer treatment - No access to a telephone - Unable to read and communicate in English, as the CONNECT intervention is currently only available in English

Study Design


Intervention

Other:
Support for Caregiver - Generic List
Receive a generic resource list
Support for Caregiver - Personalized List
Receive personalized resource list
Internet-Based Intervention - CONNECT
Receive access to CONNECT tool
Behavioral:
Patient Navigation
Complete calls with caregiver navigator

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Health Sciences National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Other Patient accrual rate Number of patients who agree to participate divided by the number of months of recruitment Upon completion of recruitment, approximately 12 months
Other Patient participation rate Proportion of eligible patients who agreed to participate Upon completion of recruitment, approximately 12 months
Other Patient retention at 12 weeks Number of patients who complete at least 75% of the 12-week assessments divided by the number randomized At 12 weeks
Other Patient retention at 24 weeks Number of patients who complete at least 75% of the 24-week assessments divided by the number randomized At 24 weeks
Primary Caregiver retention at 12 weeks Calculated as the following: Number of caregivers who complete at least 75% of the 12-week assessments divided by the number randomized. Retention will be estimated and reported along with an exact 95% confidence interval. At 12 weeks
Secondary Caregiver accrual rate Number of caregivers who agree to participate divided by the number of months of recruitment Upon completion of recruitment, approximately 12 months
Secondary Caregiver participation Proportion of eligible caregivers who agreed to participate Upon completion of recruitment, approximately 12 months
Secondary Caregiver retention at 24 weeks Number of caregivers who complete at least 75% of the 24-week assessments divided by the number randomized. At 24 weeks
Secondary Caregiver acceptability Self-report survey developed for this study to assess the degree to which caregivers found different aspects of CONNECT, the generic resource list, or usual care helpful using a Likert response from 0 (Not at all) to 5 (Very Much) At 12 weeks
Secondary Average time (minutes) needed for training for Local Practice Referral Coordinator Will be summarized across practices using mean, median, standard deviation and interquartile range. At completion of training, up to 6 months
Secondary Desired modality for training (e.g., live webinar, recorded video, paper materials) for Local Practice Referral Coordinator Will be summarized using appropriate descriptive statistics. At completion of training, up to 6 months
Secondary Average time (minutes) needed to identify and enter local resources into the Caregiver Oncology Needs Evaluation Tool (CONNECT) database Will be summarized across practices using mean, median, standard deviation and interquartile range. At conclusion of practice intervention activities, an average of 18 months
Secondary Frequency of needed resource updates in the CONNECT database Will be summarized across practices using mean, median, standard deviation and interquartile range Up to completion of practice intervention activities, an average of 18 months
Secondary Average time (minutes) spent by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm Will be summarized across practices using mean, median, standard deviation and interquartile range. Up to completion of practice intervention activities, an average of 18 months
Secondary Modality of contact (e.g. phone, virtual web meeting, email) made by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm Will be summarized using appropriate descriptive statistics. Up to completion of practice intervention activities, an average of 18 months
Secondary Number of contacts made by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm Will be summarized across practices using mean, median, standard deviation and interquartile range. Up to completion of practice intervention activities, an average of 18 months
Secondary Number of referrals facilitated by the Local Practice Referral Coordinator and Central Caregiver Navigator Will be summarized across practices using mean, median, standard deviation and interquartile range. Up to completion of practice intervention activities, an average of 18 months
Secondary Type of referrals (e.g., in person, online) facilitated by the Local Practice Referral Coordinator and Central Caregiver Navigator Will be summarized using appropriate descriptive statistics. Up to completion of practice intervention activities, an average of 18 months
Secondary Average time (minutes) needed to communicate for Central Caregiver Navigator and Local Practice Referral Coordinator Will be summarized across practices using mean, median, standard deviation and interquartile range. Up to completion of practice intervention activities, an average of 18 months
Secondary Modalities used for communication (e.g., phone, virtual web meeting, email) for Central Caregiver Navigator and Local Practice Referral Coordinator Will be summarized using appropriate descriptive statistics. Up to completion of practice intervention activities, an average of 18 months
Secondary Improvements for the future trial from Local Practice Referral Coordinator's perspectives from a survey at the end of the study Will be summarized using appropriate descriptive statistics. At completion of practice intervention activities, an average of 18 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06427369 - An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer Phase 1
Terminated NCT01228435 - IPI-504 in NSCLC Patients With ALK Translocations Phase 2
Terminated NCT02128373 - A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer N/A
Completed NCT00579215 - Lung Cancer Informational Study (LCIS) N/A
Completed NCT01556191 - Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR Phase 2
Terminated NCT00003495 - Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer Phase 2
Terminated NCT00003491 - Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer Phase 2
Active, not recruiting NCT03867175 - Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Phase 3
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Active, not recruiting NCT04267575 - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites N/A
Completed NCT02606149 - Truthful Information on Chemotherapy and Its Impact on Chemotherapy at the End of Life N/A
Completed NCT02693080 - CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy Phase 1
Completed NCT02318771 - Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Phase 1
Terminated NCT04005144 - Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Phase 1
Completed NCT03112668 - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners N/A
Completed NCT03222258 - Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
Completed NCT05025748 - Ask Questions (ASQ):Implementation of a Communication Intervention N/A
Terminated NCT05435846 - Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Phase 1
Recruiting NCT06110572 - Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation Phase 1/Phase 2
Terminated NCT02109016 - A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Phase 2